Osteoclast TGF-β Receptor Signaling Induces Wnt1 Secretion and Couples Bone Resorption to Bone Formation

Journal of Bone and Mineral Research

Volumn 31, Issue 1, 2016, Pages 76-85

  Weivoda, Megan M ^a   Ruan, Ming ^a   Pederson, Larry ^a   Hachfeld, Christine ^a   Davey, Rachel A ^b   Zajac, Jeffrey D ^b   Westendorf, Jennifer J ^a   Khosla, Sundeep ^a   Oursler, Merry Jo ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

BONE REMODELING; COUPLING; OSTEOCLAST; TGF ; WNT1

Indexed keywords

MESSENGER RNA; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; WNT1 PROTEIN; WNT1 PROTEIN, MOUSE;

ADULT; AGE; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE MATRIX; BONE METABOLISM; BONE REMODELING; BONE STRUCTURE; BOVINE; CELL CULTURE; CELL DIFFERENTIATION; CELL STIMULATION; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; GENETIC RECOMBINATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPENIA; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; YOUNG ADULT; ANIMAL; BONE DEVELOPMENT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS); TRANSGENIC MOUSE; WNT SIGNALING PATHWAY;

ANIMALS; BONE RESORPTION; GENE EXPRESSION REGULATION; MICE; MICE, TRANSGENIC; OSTEOCLASTS; OSTEOGENESIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; WNT SIGNALING PATHWAY; WNT1 PROTEIN;

EID: 84957435338     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2586     Document Type: Article

References (51)

1. Takahashi H, Epker B, Frost HM., Resorption precedes formative activity. Surg Forum. 1964; 15: 437-38.
2. Hattner R, Epker BN, Frost HM., Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature. 1965; 206 (983): 489-90.
3. Martin TJ, Sims NA., Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med. 2005; 11 (2): 76-81.
4. Delmas PD, Stenner D, Wahner HW, Mann KG, Riggs BL., Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. J Clin Invest 1983; 71 (5): 1316-21.
5. Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville (MD): Office of the Surgeon General (US); 2004 [cited 2015 July 8]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/.
6. Odvina CV, Zerwekh JE, Rao DS, et al., Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90 (3): 1294-301.
7. Chavassieux PM, Arlot ME, Reda C, et al., Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997; 100 (6): 1475-80.
8. Dai XM, Zong XH, Akhter MP, Stanley ER., Osteoclast deficiency results in disorganized matrix, reduced mineralization, and abnormal osteoblast behavior in developing bone. J Bone Miner Res. 2004; 19 (9): 1441-51.
9. Sakagami N, Amizuka N, Li M, et al., Reduced osteoblastic population and defective mineralization in osteopetrotic (op/op) mice. Micron. 2005; 36 (7-8): 688-95.
10. Guerrini MM, Sobacchi C, Cassani B, et al., Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet. 2008; 83 (1): 64-76.
11. Del Fattore A, Peruzzi B, Rucci N, et al., Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet. 2006; 43 (4): 315-25.
12. Henriksen K, Flores C, Thomsen JS, et al., Dissociation of bone resorption and bone formation in adult mice with a non-functional V-ATPase in osteoclasts leads to increased bone strength. PLoS One. 2011; 6 (11): e27482.
13. Kornak U, Kasper D, Bosl MR, et al., Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell. 2001; 104 (2): 205-15.
14. Thudium C, Moscatelli I, Flores C, et al., A comparison of osteoclast-rich and osteoclast-poor osteopetrosis in adult mice sheds light on the role of the osteoclast in coupling bone resorption and bone formation. Calcif Tissue Int. 2014; 95 (1): 83-93.
15. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ., Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci USA. 2008; 105 (52): 20764-9.
16. Henriksen K, Andreassen KV, Thudium CS, et al., A specific subtype of osteoclasts secretes factors inducing nodule formation by osteoblasts. Bone. 2012; 51 (3): 353-61.
17. Janssens K, ten Dijke P, Janssens S, Van Hul W,. Transforming growth factor-beta1 to the bone. Endocr Rev. 2005; 26 (6): 743-74.
18. Oursler MJ., Osteoclast synthesis and secretion and activation of latent transforming growth factor beta. J Bone Miner Res. 1994; 9 (4): 443-52.
19. Pfeilschifter J, Mundy GR,. Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA. 1987; 84 (7): 2024-28.
20. Neptune ER, Frischmeyer PA, Arking DE, et al., Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003; 33 (3): 407-11.
21. Janssens K, Gershoni-Baruch R, Guanabens N, et al., Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet. 2000; 26 (3): 273-75.
22. Tang Y, Wu X, Lei W, et al., TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009; 15 (7): 757-65.
23. Breen EC, Ignotz RA, McCabe L, et al., TGFβ alters growth and differentiation related gene expression in proliferating osteoblasts in vitro, preventing development of the mature bone phenotype. J Cell Physiol. 1994; 160 (2): 323-35.
24. Yang T, Grafe I, Bae Y, et al., E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-β in the bone microenvironment. Proc Natl Acad Sci USA. 2013; 110 (18): 7336-41.
25. Ota K, Quint P, Ruan M, et al., TGF-beta induces Wnt10b in osteoclasts from female mice to enhance coupling to osteoblasts. Endocrinology. 2013; 154 (10): 3745-52.
26. Ota K, Quint P, Weivoda MM, et al., Transforming growth factor beta 1 induces CXCL16 and leukemia inhibitory factor expression in osteoclasts to modulate migration of osteoblast progenitors. Bone. 2013; 57 (1): 68-75.
27. Chytil A, Magnuson MA, Wright CVE, Moses HL., Conditional inactivation of the TGF-β type II receptor using Cre:Lox. Genesis. 2002; 32 (2): 73-5.
28. Chiu WSM, McManus JF, Notini AJ, et al., Transgenic mice that express Cre recombinase in osteoclasts. Genesis. 2004; 39 (3): 178-85.
29. Stern AR, Stern MM, Van Dyke ME, et al., Isolation and culture of primary osteocytes from the long bones of skeletally mature and aged mice. Biotechniques. 2012; 52 (6): 361-73.
30. Gingery A, Bradley E, Shaw A, Oursler MJ., Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem. 2003; 89 (1): 165-79.
31. Modder UI, Oursler MJ, Khosla S, Monroe DG., Wnt10b activates the Wnt, notch, and NFkappaB pathways in U2OS osteosarcoma cells. J Cell Biochem. 2011; 112 (5): 1392-402.
32. Filgueira L., Fluorescence-based staining for tartrate-resistant acidic phosphatase (TRAP) in osteoclasts combined with other fluorescent dyes and protocols. J Histochem Cytochem. 2004; 52 (3): 411-4.
33. Roforth MM, Fujita K, McGregor UI, et al., Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone. 2014; 59: 1-6.
34. Huang da W, Sherman BT, Lempicki RA,. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4 (1): 44-57.
35. Huang da W, Lempicki RA,. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37 (1):1-13.
36. Nicolas V, Prewett A, Bettica P, et al., Age-related decreases in insulin-like growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women: implications for bone loss with aging. J Clin Endocrinol Metab. 1994; 78 (5): 1011-16.
37. Gingery A, Bradley EW, Pederson L, et al., TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp Cell Res. 2008; 314 (15): 2725-38.
38. Keller J, Catala-Lehnen P, Huebner AK, et al., Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. Nat Commun. 2014; 5: 5215.
39. Lotinun S, Kiviranta R, Matsubara T, et al., Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest. 2013; 123 (2): 666-81.
40. Takeshita S, Fumoto T, Matsuoka K, et al., Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. J Clin Invest. 2013; 123 (9): 3914-24.
41. Sanchez-Fernandez MA, Gallois A, Riedl T, Jurdic P, Hoflack B., Osteoclasts control osteoblast chemotaxis via PDGF-BB/PDGF receptor beta signaling. PLoS One. 2008; 3 (10): e3537.
42. Gong Y, Slee RB, Fukai N, et al., LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001; 107 (4): 513-23.
43. Little RD, Carulli JP, Del Mastro RG, et al., A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002; 70 (1): 11-9.
44. Balemans W, Ebeling M, Patel N, et al., Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10 (5): 537-43.
45. Balemans W, Patel N, Ebeling M, et al., Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002; 39: 91-7.
46. Riddle RC, Diegel CR, Leslie JM, et al., Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition. PLoS One. 2013; 8 (5): e63323.
47. Cui Y, Niziolek PJ, MacDonald BT, et al., Lrp5 functions in bone to regulate bone mass. Nat Med. 2011; 17 (6): 684-91.
48. Fahiminiya S, Majewski J, Mort J, et al., Mutations in WNT1 are a cause of osteogenesis imperfecta. J Med Genet. 2013; 50 (5): 345-48.
49. Keupp K, Beleggia F, Kayserili H, et al., Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet. 2013; 92 (4): 565-74.
50. Laine CM, Joeng KS, Campeau PM, et al., WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med. 2013; 368 (19): 1809-16.
51. Pyott SM, Tran TT, Leistritz DF, et al., WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet. 2013; 92 (4): 590-97.